Targeting Drug-Resistant Melanoma with Novel Ligand-Drug Conjugates

Despite significant advancements in treating melanoma, a highly lethal form of skin cancer, with therapies like BRAF-V600E and PD-1 inhibitors, many patients eventually develop drug resistance. This resistance renders existing treatments ineffective, creating a critical need for alternative therapeutic strategies. This study addresses the urgent need for new approaches that can selectively deliver cytotoxic drugs to melanoma cells, circumventing resistance mechanisms.

The synthesized drug-MT-II conjugates demonstrated strong binding interactions with the MC1R, confirming their ability to target melanoma cells. Crucially, these conjugates induced selective drug delivery specifically to A375 melanoma cells via the MT-II moiety, ensuring the cytotoxic payload reached its intended target. When camptothecin was used as the cytotoxic component, the resulting camptothecin-MT-II (compound 1) proved highly effective. > Compound 1 significantly inhibited A375 melanoma cell growth with an IC50 (half maximal inhibitory concentration) of just 16 nM, indicating potent anti-proliferative activity at very low concentrations compared to untreated control cells. This selective targeting and potent inhibition highlight the potential of this conjugate platform.